MANKIND PHARMA
Quarterly Results Analysis [Mar2025]
MANKIND PHARMA Quarterly Results
Consolidated | Mar2025 UnAudited |
Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹3,079 Cr | ₹3,230 Cr | ₹3,077 Cr | ₹2,893 Cr | ₹2,422 Cr | ₹2,607 Cr | ₹2,708 Cr | ₹2,579 Cr |
Expenses | ₹2,396 Cr | ₹2,400 Cr | ₹2,226 Cr | ₹2,212 Cr | ₹1,836 Cr | ₹2,000 Cr | ₹2,025 Cr | ₹1,924 Cr |
Operating Income | ₹683 Cr | ₹830 Cr | ₹850 Cr | ₹682 Cr | ₹586 Cr | ₹607 Cr | ₹683 Cr | ₹655 Cr |
Other Income | ₹251 Cr | ₹77 Cr | ₹109 Cr | ₹101 Cr | ₹92 Cr | ₹70 Cr | ₹60 Cr | ₹59 Cr |
Interest | ₹191 Cr | ₹221 Cr | ₹7 Cr | ₹11 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹6 Cr |
Depreciation | ₹231 Cr | ₹192 Cr | ₹106 Cr | ₹108 Cr | ₹100 Cr | ₹110 Cr | ₹96 Cr | ₹87 Cr |
Profit Before Tax | ₹513 Cr | ₹494 Cr | ₹847 Cr | ₹664 Cr | ₹570 Cr | ₹558 Cr | ₹638 Cr | ₹620 Cr |
Profit After Tax | ₹427 Cr | ₹381 Cr | ₹656 Cr | ₹539 Cr | ₹475 Cr | ₹455 Cr | ₹508 Cr | ₹489 Cr |
EPS | ₹10.20 | ₹9.22 | ₹16.31 | ₹13.39 | ₹11.76 | ₹11.33 | ₹12.51 | ₹12.15 |
Industry Peers & Returns | 1W | 1M | 1Y |
MANKIND PHARMA | 0.2% | -2.4% | 12.5% |
SUN PHARMACEUTICAL INDUSTRIES | 1.6% | -2.9% | 17.2% |
DIVIS LABORATORIES | 1.5% | 10.4% | 51.9% |
CIPLA | 2.3% | 1.9% | 2.8% |
TORRENT PHARMACEUTICALS | 1.4% | 1.3% | 17% |
DR REDDYS LABORATORIES | 5.7% | 14.1% | 15.2% |
ZYDUS LIFESCIENCES | 5.1% | 10.9% | -4.4% |
LUPIN | 2% | -2.2% | 27.9% |
AUROBINDO PHARMA | 1.5% | -0.2% | -3.3% |
MANKIND PHARMA Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -4.66 % |
Y-o-Y | 27.13 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Mar2025 | ₹3,079 Cr | -4.66 | |
Dec2024 | ₹3,230 Cr | 4.99 | |
Sep2024 | ₹3,077 Cr | 6.33 | |
Jun2024 | ₹2,893 Cr | 19.45 | |
Mar2024 | ₹2,422 Cr | -7.09 | |
Dec2023 | ₹2,607 Cr | -3.74 | |
Sep2023 | ₹2,708 Cr | 5.02 | |
Jun2023 | ₹2,579 Cr | - |
MANKIND PHARMA Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -17.67 % |
Y-o-Y | 16.53 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Mar2025 | ₹683 Cr | -17.67 | |
Dec2024 | ₹830 Cr | -2.38 | |
Sep2024 | ₹850 Cr | 24.68 | |
Jun2024 | ₹682 Cr | 16.28 | |
Mar2024 | ₹586 Cr | -3.33 | |
Dec2023 | ₹607 Cr | -11.16 | |
Sep2023 | ₹683 Cr | 4.25 | |
Jun2023 | ₹655 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -13.62 % |
Y-o-Y | -8.31 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Mar2025 | 22.19% | -13.62 | |
Dec2024 | 25.69% | -7.02 | |
Sep2024 | 27.63% | 17.28 | |
Jun2024 | 23.56% | -2.64 | |
Mar2024 | 24.2% | 4.04 | |
Dec2023 | 23.26% | -7.74 | |
Sep2023 | 25.21% | -0.71 | |
Jun2023 | 25.39% | - |
MANKIND PHARMA Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | 11.96 % |
Y-o-Y | -10.08 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Mar2025 | ₹427 Cr | 11.96 | |
Dec2024 | ₹381 Cr | -41.94 | |
Sep2024 | ₹656 Cr | 21.73 | |
Jun2024 | ₹539 Cr | 13.62 | |
Mar2024 | ₹475 Cr | 4.24 | |
Dec2023 | ₹455 Cr | -10.34 | |
Sep2023 | ₹508 Cr | 3.73 | |
Jun2023 | ₹489 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | 17.46 % |
Y-o-Y | -29.25 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2025 | 13.86 % | 17.46 | |
Dec2024 | 11.8 % | -44.68 | |
Sep2024 | 21.33 % | 14.49 | |
Jun2024 | 18.63 % | -4.90 | |
Mar2024 | 19.59 % | 12.20 | |
Dec2023 | 17.46 % | -6.88 | |
Sep2023 | 18.75 % | -1.21 | |
Jun2023 | 18.98 % | - |
MANKIND PHARMA Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | 10.63 % |
Y-o-Y | -13.27 % |
Quarters | EPS | % Change | |
---|---|---|---|
Mar2025 | ₹10.2 | 10.63 | |
Dec2024 | ₹9.22 | -43.47 | |
Sep2024 | ₹16.31 | 21.81 | |
Jun2024 | ₹13.39 | 13.86 | |
Mar2024 | ₹11.76 | 3.80 | |
Dec2023 | ₹11.33 | -9.43 | |
Sep2023 | ₹12.51 | 2.96 | |
Jun2023 | ₹12.15 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD